News Agency
Men's Weekly

Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024

  • Written by PR Newswire
Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024

US$3.2 million (A$4.8m) R&D tax incentive rebate received from Australian Tax Office and XanaMIA Phase 2b Alzheimer's disease trial to commence shortly with initial results expected in first half of 2025  

SYDNEY, Nov. 28, 2023 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that enrolment in the XanaCIDD Phase 2a...

Read more: Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment...

Commercial Property Buyers Agent Helping You Make Smarter Investment Decisions

Investing in commercial real estate is a different beast compared to residential property, it’s less about emotion and more about strategy, numbers, and long-term returns. In this space, a commercial property buyers agent acts like a skilled strategist, helping investors identify... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion